This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.

NONS for COVID-19 Treatment [COVID-19]

  • Research type

    Research Study

  • Full title

    Clinical Efficacy of Nitric Oxide Nasal Spray (NONS) for the Treatment of Mild COVID-19 Infection

  • IRAS ID

    287727

  • Contact name

    Stephen Winchester

  • Contact email

    s.winchester@nhs.net

  • Sponsor organisation

    Ashford and St Peter's Hospitals NHS Foundation Trust

  • Eudract number

    2020-004994-27

  • Duration of Study in the UK

    1 years, 0 months, 1 days

  • Research summary

    There is currently a worldwide pandemic caused by the respiratory virus SARS-CoV-2, or coronavirus for short. For a lot of people infected by COVID-19, they exhibit mild symptoms: dry cough, mild fever, tiredness, loss of smell. We are hoping Nitric Oxide Nasal Spray can act as suitable treatment for individuals with a mild infection.

    There are currently no known drugs that can be administered as specific treatment against mild COVID-19 symptoms. NHS guidance is currently to quarantine for 10 days at home if you are experiencing COVID-19 symptoms.

    The study is designed to look at the potential effects of nitric oxide (NO) in treating mild COVID-19 symptoms. Although initial data is promising, this study will help clarify the effects and potential of nitric oxide in COVID-19 treatment.

    The NO (technically labelled drug) is delivered through a nasal spray over the course of 9 days. Current research indicates that nitric oxide is effective against viral infections and we are hoping to replicate its success against coronavirus by providing it as a treatment option to those with mild COVID-19 symptoms.

  • REC name

    London - Brent Research Ethics Committee

  • REC reference

    20/LO/1209

  • Date of REC Opinion

    16 Nov 2020

  • REC opinion

    Further Information Favourable Opinion